In the original article, there was an error. Themanuscript states that “Apixaban and edoxaban need to be administered twice a day” whereas Edoxaban needs to be administered only once a day as stated in the European Product Information and Summary of Product Characteristics. A correction has been made to the section PHARMACOKINETIC OF DOACS, subsection Direct Factor Xa Inhibitors: “Apixaban, edoxaban and rivaroxaban are selective inhibitors of Xa factor (FXa) by binding its active site both when free or thrombin-bound..
Corrigendum: Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs (Frontiers in Neurology, (2018), 9, 10.3389/fneur.2018.01067)
Palleria C.;De Sarro G.;Russo E.
2020-01-01
Abstract
In the original article, there was an error. Themanuscript states that “Apixaban and edoxaban need to be administered twice a day” whereas Edoxaban needs to be administered only once a day as stated in the European Product Information and Summary of Product Characteristics. A correction has been made to the section PHARMACOKINETIC OF DOACS, subsection Direct Factor Xa Inhibitors: “Apixaban, edoxaban and rivaroxaban are selective inhibitors of Xa factor (FXa) by binding its active site both when free or thrombin-bound..File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
